Chronic Myelogenous Leukemia (CML) Treatments
Find Chronic Myelogenous Leukemia (CML) Treatments
Iclusig
What is Iclusig (Ponatinib)?
Top Global Experts
Related Clinical Trials
Summary: This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period of improvement (recurrent), or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a chemot...
Summary: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to \< 18 years with advanced leukemias, lymphomas, and solid tumors.
Summary: This phase II trial studies how well ponatinib hydrochloride works as second line therapy in treating patients with chronic myeloid leukemia in chronic phase that has not responded to initial treatment (first line) with imatinib mesylate, dasatinib, or nilotinib or cannot tolerate imatinib mesylate, dasatinib, or nilotinib. Ponatinib hydrochloride may stop or control the growth of cancer cells by ...
Related Latest Advances
Brand Information
- Newly diagnosed Ph+ ALL in combination with chemotherapy.
- As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL.
- Chronic phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors.
- Accelerated phase (AP) or blast phase (BP) CML for whom no other kinase inhibitors are indicated.
- T315I-positive CML (chronic phase, accelerated phase, or blast phase).
- 10 mg of ponatinib: Oval, white to off-white, biconvex, debossed "NZ" on one side and plain on the other side
- 15 mg of ponatinib: Round, white, biconvex, debossed "A5" on one side and plain on the other side
- 30 mg of ponatinib: Round, white, biconvex, debossed "C7" on one side and plain on the other side
- 45 mg of ponatinib: Round, white, biconvex, debossed "AP4" on one side and plain on the other side
- Arterial Occlusive Events
- Venous Thromboembolic Events
- Heart Failure
- Hepatotoxicity
- Hypertension
- Pancreatitis
- Neuropathy
- Ocular Toxicity
- Hemorrhage
- Fluid Retention
- Cardiac Arrhythmias
- Myelosuppression
- Tumor Lysis Syndrome
- Reversible Posterior Leukoencephalopathy Syndrome
- Impaired Wound Healing and Gastrointestinal Perforation





